









市場行情
/
股票
/
nasdaq-ew
/

Edwards Lifesciences Corp

83.380USD

+0.300+0.36%

收盤 12/15, 16:00（美東）報價延遲15分鐘

48.42B總市值

35.51本益比TTM



Edwards Lifesciences Corp

83.380

+0.300+0.36%

概覽公司財務分析

概覽

公司

財務

分析

關於 Edwards Lifesciences Corp 公司

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Edwards Lifesciences Corp簡介



公司代碼EW

公司名稱Edwards Lifesciences Corp

上市日期Mar 27, 2000

CEOZovighian (Bernard J)

員工數量15800

證券類型Ordinary Share

年結日Mar 27

公司地址One Edwards Way

城市IRVINE

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編92614

電話19492502500

網址https://www.edwards.com

公司代碼EW

上市日期Mar 27, 2000

CEOZovighian (Bernard J)

Edwards Lifesciences Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

Mr. Kieran T. Gallahue

Independent Director

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

名稱

名稱/職務

職務

持股

持股變動

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

業務USD

名稱

營收

佔比

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

地區USD

名稱

營收

佔比

United States

889.70M

58.07%

Europe

378.20M

24.68%

Rest of the world

169.00M

11.03%

Japan

95.30M

6.22%

業務

地區

業務USD

名稱

營收

佔比

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

12.08%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

其他

71.57%

持股股東

佔比

The Vanguard Group, Inc.

12.08%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

其他

71.57%

股東類型

持股股東

佔比

Investment Advisor

46.84%

Investment Advisor/Hedge Fund

30.85%

Hedge Fund

3.47%

Pension Fund

2.27%

Research Firm

2.17%

Bank and Trust

1.95%

Sovereign Wealth Fund

1.37%

Individual Investor

0.93%

Endowment Fund

0.83%

其他

9.33%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

2452

517.66M

93.53%

2025Q3

2537

517.80M

94.00%

-1.50M

2025Q2

2614

519.17M

94.35%

-5.19M

2025Q1

2599

525.51M

93.66%

-25.15M

2024Q4

2585

522.16M

89.45%

+17.15M

2024Q3

2546

504.88M

87.53%

-10.03M

2024Q2

2541

515.71M

87.77%

+1.93M

2024Q1

2555

513.21M

86.74%

-8.92M

2023Q4

2556

503.19M

87.55%

-12.35M

2023Q3

2509

516.79M

88.03%

-521.37K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

69.74M

11.88%

+793.20K

+1.15%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

30.89M

5.26%

-1.39M

-4.31%

Jun 30, 2025

State Street Investment Management (US)

25.63M

4.37%

-149.08K

-0.58%

Jun 30, 2025

Wellington Management Company, LLP

19.83M

3.38%

-9.31M

-31.95%

Jun 30, 2025

JP Morgan Asset Management

20.09M

3.42%

+3.72M

+22.71%

Jun 30, 2025

Jennison Associates LLC

11.67M

1.99%

+1.58M

+15.71%

Jun 30, 2025

Geode Capital Management, L.L.C.

12.72M

2.17%

+45.55K

+0.36%

Jun 30, 2025

Walter Scott & Partners Ltd.

8.91M

1.52%

-150.07K

-1.66%

Jun 30, 2025

Union Investment Privatfonds GmbH

8.59M

1.46%

+4.67M

+119.31%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares U.S. Medical Devices ETF

4.72%

Future Fund Long/Short ETF

3.86%

iShares Health Innovation Active ETF

3.65%

Global X Aging Population ETF

3.31%

Acruence Active Hedge US Equity ETF

2.58%

First Trust Indxx Medical Devices ETF

2.23%

State Street SPDR S&P Health Care Equipment ETF

1.88%

JPMorgan Healthcare Leaders ETF

1.8%

PGIM Jennison Better Future ETF

1.78%

ROBO Global Healthcare Technology & Innovation ETF

1.73%

iShares U.S. Medical Devices ETF

佔比4.72%

Future Fund Long/Short ETF

佔比3.86%

iShares Health Innovation Active ETF

佔比3.65%

Global X Aging Population ETF

佔比3.31%

Acruence Active Hedge US Equity ETF

佔比2.58%

First Trust Indxx Medical Devices ETF

佔比2.23%

State Street SPDR S&P Health Care Equipment ETF

佔比1.88%

JPMorgan Healthcare Leaders ETF

佔比1.8%

PGIM Jennison Better Future ETF

佔比1.78%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.73%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

May 07, 2020

Split

1→3

公告日期

類型

比率

May 07, 2020

Split

1→3

常見問題

Edwards Lifesciences Corp的前五大股東是誰？



Edwards Lifesciences Corp的前五大股東如下：
The Vanguard Group, Inc.
持有股份：69.74M
佔總股份比例：11.88%。
BlackRock Institutional Trust Company, N.A.
持有股份：30.89M
佔總股份比例：5.26%。
State Street Investment Management (US)
持有股份：25.63M
佔總股份比例：4.37%。
Wellington Management Company, LLP
持有股份：19.83M
佔總股份比例：3.38%。
JP Morgan Asset Management
持有股份：20.09M
佔總股份比例：3.42%。